Drug Discovery@nature.com 28 February 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 28 February 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Collections  LIGHT-SHEET MICROSCOPY  Produced with support from:  Carl Zeiss Microscopy    News Top Shire shifts towards rare diseases doi:10.1038/nbt0214-114 Shire's $4.2-billion acquisition of ViroPharma is the latest move by the biotech to focus its pipeline on rare diseases such as hereditary angioedema. Full Text PARP inhibitors' revival doi:10.1038/nbt0214-115b Improved companion diagnostic tests could broaden the target population of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of cancer. Full Text It's official: biologics are pharma's darlings doi:10.1038/nbt0214-117 A new report has quantified big pharma’s shift in focus from small-molecule drugs to biologics. Full Text Straight talk with...Jeremy Farrar doi:10.1038/nm0214-112 Jeremy Farrar discusses the issues he will be addressing as the new head of the UK-based Wellcome Trust. Full Text Analysis Top Europe's upwelling doi:10.1038/scibx.2014.188 SciBX's third annual comprehensive analysis of public-private partnerships and early stage venture financing activity shows that Europe's PPP activity in 2013 surpassed that of the US in dramatic fashion. Full Text Biosimilar competition: lessons from Europe doi:10.1038/nrd4210 Grabowski and colleagues analyse the European market uptake of biosimilar versions of two major therapeutic biologics — epoetin alfa and filgrastim — and discuss the implications for the future development of the market for biosimilars. Full Text Research Highlights Top Kidney disease: Targeting a faulty filter doi:10.1038/nrd4234 ML204, a small-molecule inhibitor of transient receptor potential channel 5, protects against injury in a mouse model of kidney damage. Full Text Phenotypic screening: A more rapid route to target deconvolution doi:10.1038/nrd4243 Combining activity-based protein profiling with phenotypic screening to improve drug target identification. Full Text Neurodevelopmental disorders: The gut–microbiome–brain connection doi:10.1038/nrd4235 Targeting the gut microbiota could be useful for treating behavioural symptoms in autism spectrum disorder. Full Text Research & Reviews Top PI3K and cancer: lessons, challenges and opportunities doi:10.1038/nrd4204 Fruman and Rommel discuss the complexity of the phosphoinositide 3-kinase signalling network in cancer, address challenges associated with therapeutic intervention and propose strategies to guide future research efforts. Full Text Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases? doi:10.1038/nrd4189 The authors discuss how herpesvirus-encoded G protein-coupled receptors — which can hijack downstream signalling pathways in host cells — could be promising targets in certain inflammatory and proliferative diseases. Full Text The role of ligand efficiency metrics in drug discovery doi:10.1038/nrd4163 This article discusses how the application of ligand efficiency metrics (the molecular properties required to gain binding affinity for a drug target) has the potential to increase the quality of drug candidates. Full Text Inflammasomes in the CNS doi:10.1038/nrn3638 This Review describes our current understanding of the functions of different inflammasomes in the CNS and their roles in neurological diseases. Full Text Drug Discovery JOBS of the week University of Michigan Postdoc in Drug Delivery / Biomaterials / / Immunoengineering University of Michigan Postdoc Cancer Biology for Drug Discovery Italian Institute of Technology (ITT) Drug Discovery Opportunities at D. E. Shaw Research D. E. Shaw Research Tier 2 Canada Research Chair in Molecular Pharmacology and Drug Discovery University of Ottawa More Science jobs from Drug Discovery EVENT 20th International Symposium on Microsomes and Drug Oxidations (MDO) 18.05.14 Leinfelden-Echterdingen, Germany More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.